Revvity, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US7140461093
USD
102.55
-0.71 (-0.69%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Revvity, Inc. stock-summary
stock-summary
Revvity, Inc.
Pharmaceuticals & Biotechnology
PerkinElmer Inc. is a provider of products, services and solutions for the diagnostics, life sciences and applied markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. Its Discovery & Analytical Solutions segment serves the life sciences and applied markets. Through the Diagnostics Segment, it offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals. It provides early detection for genetic disorders from pregnancy to early childhood, and infectious disease testing for the diagnostics market. It offers its product under various brands, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BoBs, chemagic, FragilEase, Genoglyphix, GSP, PG-Seq, PG-Find, Protein Clear, ProteinEXact and QSight, Glutomatic, Honigs Regression, HyperDSC, Inframatic, LAMBDA, NexION, NEN, OneSource, Opera Phenix, Operetta CLS and OsteoSense.
Company Coordinates stock-summary
Company Details
155 Federal St Ste 700 , BOSTON MA : 02110-1727
stock-summary
Tel: 1 781 6635776
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 103 Schemes (57.41%)

Foreign Institutions

Held by 281 Foreign Institutions (24.63%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Alexandros Michas
Independent Non-Executive Chairman of the Board
Mr. Prahlad Singh
President, Chief Executive Officer, Director
Dr. Peter Barrett
Independent Director
Mr. Samuel Chapin
Independent Director
Dr. Sylvie Gregoire
Independent Director
Mr. Michel Vounatsos
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
720 Million
(Quarterly Results - Jun 2025)
Net Profit:
55 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 10,015 Million (Small Cap)

stock-summary
P/E

33.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.34%

stock-summary
Debt Equity

0.29

stock-summary
Return on Equity

4.20%

stock-summary
Price to Book

1.33